FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

20:01 EDT 16 Jul 2018 | Cancer Connect

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC). This […]

More From BioPortfolio on "FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer"